Eight patients with pancreatic neoplasia were confirmed by surgery or fine-needle aspiration (10% yield of screening); of these, six patients had benign intraductal papillary mucinous neoplasms (IPMNs), one had an IPMN that progressed to invasive ductal adenocarcinoma, and one had a PanIN-1.
The Food and Drug Administration has approved Velcade to treat a type of cancer called multiple myeloma. Velcade should only be used in people who have already been treated with two other types of chemotherapy (drugs used to kill cancer cells), and whose cancer has still progressed on the most recent therapy.Velcade is a new type of cancer drug called a proteasome inhibitor.Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells.elcade is a new type of cancer drug called a proteasome inhibitor. Proteasomes are enzymes found in cells, and play a role in regulating cell function and growth. Velcade blocks the activity of proteasomes. This blockade can lead to death of cancer cells.
Velcade (bortezomib) is an antineoplastic agent available for intravenous injection. The proteasome is an enzyme complex that exists in all cells and plays an important role in degrading proteins that control the cell cycle and cellular processes.ortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma. The compound bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins.